• Choose Medicine

Faq Information

How effective is palbociclib? Date : Thursday 16 Feb, 2023
FAQ Summary
The median progression-free survival for the 23 patients who got palbociclib as...
FAQ Content:
The median progression-free survival for the 23 patients who got palbociclib as second-line therapy for metastatic breast cancer was 13.3 months (95% CI 4.1-22.4 months). The median progression-free survival among the 7 women who received palbociclib as third-line treatment was 6.0 months (95% CI 0.9-11.1 months).
FAQ Statistics:
Viewed : 42
Current Reviews : 0
  • Choose Medicine